BioNTech to Showcase Oncology Pipeline Progress at ASCO 2025

BioNTech SE ( (BNTX) ) has provided an announcement.

On May 27, 2025, BioNTech SE announced its plans to present clinical trial data from its oncology pipeline at the ASCO Annual Meeting in Chicago from May 30 to June 3, 2025. The presentations will showcase progress in BioNTech’s clinical programs, including mRNA cancer immunotherapies and next-generation immunomodulators. Highlights include data on BNT327, an investigational anti-PD-L1xVEGF-A antibody, and BNT324/DB-1311, a B7H3-targeted ADC candidate. These developments underline BioNTech’s commitment to advancing its oncology pipeline and its strategic focus on becoming a diversified multi-product oncology company.

The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

Spark’s Take on BNTX Stock

According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.

BioNTech’s stock score is primarily impacted by financial performance challenges, including unprofitability and cash flow volatility. Technical analysis and valuation metrics provide limited support due to mixed signals and a negative P/E ratio. The earnings call offers some optimism with strategic advancements in oncology, though offset by financial losses and high expenses.

To see Spark’s full report on BNTX stock, click here.

More about BioNTech SE

BioNTech SE is a global next-generation immunotherapy company focused on pioneering novel therapies for cancer and other serious diseases. The company utilizes a diverse array of computational discovery and therapeutic modalities to rapidly develop innovative biopharmaceuticals. BioNTech’s oncology portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates and CAR T cell therapies. The company also collaborates with multiple global pharmaceutical partners to advance its research and development efforts.

Average Trading Volume: 1,126,778

Technical Sentiment Signal: Sell

Current Market Cap: $23.72B

Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.